Skip to content
2000
Volume 7, Issue 1
  • ISSN: 1573-398X
  • E-ISSN: 1875-6387

Abstract

Chronic medical conditions occur in more than half of the patients with COPD. They contribute to COPDrelated hospitalizations and they have been shown to prolong length of stay in patients with COPD. The presence of COPD can adversely impacts patients admitted to hospital with other conditions including pneumonia. Cardiovascular diseases are the leading causes of death in patients with COPD. Pharmacological treatment of COPD may adversely affect heart disease and diabetes. Recent studies highlight systemic morbidity with use of inhaled medications. Pulmonary hypert Musculoskeletal dysfunction, a systemic manifestation of COPD, contributes to exercise limitation. Osteoporosis occurs in patients with COPD even independent of oral steroid use. Gastro esophageal reflux symptoms are more common in patients with an FEV1 < 50%. Mortality is higher with poor glycemic control during a COPD exacerbation. Systemic inflammation in COPD is mediated by IL-6, IL-8, CRP and TNF α with the latter two contributing to anemia. CRP levels in COPD patients are associated with poor quality of life, reduced exercise endurance and correlate inversely with the 6 minute walk test. Clinicians needs to be aware of these co-morbidities and must evaluate their COPD patients accordingly. Early intervention can decrease intensity of the co-morbidity and improve quality of life in COPD patients.

Loading

Article metrics loading...

/content/journals/crmr/10.2174/157339811794109282
2011-02-01
2025-12-10
Loading full text...

Full text loading...

/content/journals/crmr/10.2174/157339811794109282
Loading

  • Article Type:
    Research Article
Keyword(s): acute myocardial infarctions; Airway Obstruction; Anemia; angiography; atherogenesis; atheroma; atherosclerotic process; atrial fibrillation; Benzodiazepine receptor antagonists; bone mineral density; brain natriuretic peptide (BNP); cardiac dysrhythmias; cardiovascular disease; catecholamine; Chronic Bronchitis; co-morbidities; congestive heart failure (CHF); contractile protein metabolism; COPD; coronary artery disease (CAD); cytokines; deep venous thrombosis; diabetes; Emphysema; erythropoietin; fibrinogen; fluticasonesalmeterol; Gastro Esophageal Reflux (GERD); glucocorticoid; heart catheterization; hyperglycemia; Hyperinflation; Hypoxia; inhaled glucocorticoid; insomnia; ipratropium bromide; leucocytes; lipopolysaccharide binding protein; Long term oxygen therapy (LTOT); low density lipoproteins; Lung cancer; meta-analysis; metabolic syndrome; mortality; multi system disease; Multifocal atrial tachycardia (MAT); Obstructive sleep apnea (OSA); osteoclastogenesis; Osteoporosis; osteoporosis; oxidative stress; Pneumonia; pneumonia; Premature ventricular contractions (PVC's); proteolysis; pulmonary artery pressure (PAP); pulmonary embolism; Pulmonary hypertension; pulmonary rehabilitation; randomized control trials (RCTs); Reactive oxygen species (ROS); Rhythmic eye movement (REM); Right Ventricular (RV) Dysfunction; Skeletal muscle dysfunction; squamous cell carcinoma; Systemic inflammation; theophylline; tiotropium; TNF; Tumor necrotic factor (TNF)
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test